Search Results - "Headlee, D"

The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol by Moyer, Matthew T., Sharzehi, Setareh, Mathew, Abraham, Levenick, John M., Headlee, Brandy D., Blandford, Jonathan T., Heisey, Heather D., Birkholz, James H., Ancrile, Brooke B., Maranki, Jennifer L., Gusani, Niraj J., McGarrity, Thomas J., Dye, Charles E.

“…Endoscopic ultrasound (EUS)−guided chemoablation with ethanol lavage followed by infusion of paclitaxel is effective for the treatment of mucinous pancreatic…”
Get full text

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms by SAUSVILLE, Edward A, ARBUCK, Susan G, JING, Xiu-Xian, ROBERGE, Michel, FUSE, Eiichi, KUWABARA, Takashi, SENDEROWICZ, Adrian M, MESSMANN, Richard, HEADLEE, Donna, BAUER, Kenneth S, LUSH, Richard M, MURGO, Anthony, FIGG, William D, LAHUSEN, Tyler, JAKEN, Susan

“…To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine),…”
Get full text

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms by Senderowicz, A M, Headlee, D, Stinson, S F, Lush, R M, Kalil, N, Villalba, L, Hill, K, Steinberg, S M, Figg, W D, Tompkins, A, Arbuck, S G, Sausville, E A

“…We conducted a phase I trial of the cyclin-dependent kinase inhibitor, flavopiridol (National Service Center [NSC] 649890), to determine the maximum-tolerated…”
Get more information

The Durability of EUS-Guided Chemoablation of Mucinous Pancreatic Cysts: A Long-Term Follow-Up of the CHARM trial by Lester, Courtney, Walsh, Leonard, Hartz, Kayla M., Mathew, Abraham, Levenick, John M., Headlee, Brandy D., Heisey, Heather D., Birkholz, James H., Dixon, Matthew, Maranki, Jennifer L., Gusani, Niraj J., Dye, Charles E., Moyer, Matthew T.

“…Pancreatic cancer has known precursor lesions with potential to develop into malignancy over time. At least 20% of pancreatic cancer evolves from mucinous…”
Get full text

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer by BERGAN, R. C, REED, E, STEINBERG, S. M, BLAGOSKLONNY, M. V, MYERS, C. E, HEADLEE, D, BRAWLEY, O, CHO, H.-K, FIGG, W. D, TOMPKINS, A, LINEHAN, W. M, KOHLER, D

“…Micromolar concentrations of tamoxifen inhibit the activity of protein kinase C and were recently shown to inhibit prostate cancer cell growth in preclinical…”
Get full text

Phase I study of phenylacetate administered twice daily to patients with cancer by Thibault, A, Samid, D, Cooper, M R, Figg, W D, Tompkins, A C, Patronas, N, Headlee, D J, Kohler, D R, Venzon, D J, Myers, C E

“…The growth-inhibiting and differentiating effects of sodium phenylacetate against hematopoietic and solid tumor cell lines has aroused clinical interest in its…”
Get more information

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer by THIBAULT, A, COOPER, M. R, MYERS, C. E, FIGG, W. D, VENZON, D. J, SARTOR, A. O, TOMPKINS, A. C, WEINBERGER, M. S, HEADLEE, D. J, MCCALL, N. A, SAMID, D

“…Phenylacetate has recently been shown to suppress tumor growth and promote differentiation in experimental models. A phase I trial of phenylacetate was…”
Get full text

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer by Sartor, O, Cooper, M, Weinberger, M, Headlee, D, Thibault, A, Tompkins, A, Steinberg, S, Figg, W D, Linehan, W M, Myers, C E

“…The best treatment for patients with "hormone-refractory" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone…”
Get more information

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables by Dawson, N A, Cooper, M R, Figg, W D, Headlee, D J, Thibault, A, Bergan, R C, Steinberg, S M, Sausville, E A, Myers, C E, Sartor, O

“…A prospective Phase II clinical trial was conducted to assess the clinical activity of a pharmacokinetically guided suramin regimen in patients who had…”
Get more information

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal by DAWSON, N, FIGG, W. D, SAUSVILLE, E, LINEHAN, W. M, REED, E, SARTOR, O, BRAWLEY, O. W, BERGAN, R, COOPER, M. R, SENDEROWICZ, A, HEADLEE, D, STEINBERG, S. M, SUTHERLAND, M, PATRONAS, N

“…Management of prostate cancer progression after failure of initial hormonal therapy is controversial. Recently, the activity of the simple discontinuation of…”
Get full text

Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine by Piscitelli, S C, Thibault, A, Figg, W D, Tompkins, A, Headlee, D, Lieberman, R, Samid, D, Myers, C E

“…Phenylacetate, an inducer of tumor cytostasis and differentiation, shows promise as a relatively nontoxic antineoplastic agent. Phenylacetate, however, has an…”
Get more information

A phase I study of pentosan polysulfate sodium in patients with advanced malignancies by Lush, R. M., Figg, W. D., Pluda, J. M., Bitton, R., Headlee, D., Kohler, D., Reed, E., Sartor, O., Cooper, M. R.

“…Background: Pentosan polysulfate (xylanopolyhydrogensulfate) is a semi-synthetic sulfated heparinoid polysaccharide which has been used as an anticoagulant for…”
Get full text

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin by Bitton, R J, Figg, W D, Venzon, D J, Dalakas, M C, Bowden, C, Headlee, D, Reed, E, Myers, C E, Cooper, M R

“…To describe pharmacologic variables correlated with the development of neurologic toxicity in patients treated with suramin. Eighty-one patients were treated…”
Get more information

Suramin-induced neutropenia by Dawson, N.A., Lush, R.M., Steinberg, S.M., Tompkins, A.C., Headlee, D.J., Figg, W.D.

“…This paper presents a retrospective review of 6 cases of severe neutropenia attributed to suramin, the response to granulocyte-colony stimulating factor…”
Get full text

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma by RYAN, Qin C, HEADLEE, Donna, MELILLO, Giovanni, ELSAYED, Yusri, MONGA, Manish, KALNITSKIY, Mikhail, ZWIEBEL, James, SAUSVILLE, Edward A, ACHARYA, Milin, SPARREBOOM, Alex, TREPEL, Jane B, YE, Joseph, FIGG, William D, HWANG, Kyunghwa, EUN JOO CHUNG, MURGO, Anthony

“…The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the…”
Get full text

Adaptive control with feedback strategies for suramin dosing by Cooper, M R, Lieberman, R, La Rocca, R V, Gernt, P R, Weinberger, M S, Headlee, D J, Kohler, D R, Goldspiel, B R, Peck, C C, Myers, C E

“…Suramin, a drug used in the treatment of parasitic diseases, is currently being evaluated in clinical trials as an antineoplastic agent. The use of therapeutic…”
Get more information

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer by BERGAN, R. C, WALLS, R. G, FIGG, W. D, DAWSON, N. A, HEADLEE, D, TOMPKINS, A, STEINBERG, S. M, REED, E

“…African-American males have a higher incidence of prostate cancer than non-African-American males and an overall poorer prognosis. Environmental factors such…”
Get full text

Anaphylactoid reaction with suramin by Thibault, A, Figg, W D, Cooper, M R, Prindiville, S A, Sartor, A O, Headlee, D J, Myers, C E

“…Suramin, a drug used to treat parasitic diseases, is currently being investigated as a treatment for metastatic prostate cancer. A 73-year-old man had an…”
Get more information

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms by TAN, Antoinette R, HEADLEE, Donna, SENDEROWICZ, Adrian M, MESSMANN, Richard, SAUSVILLE, Edward A, ARBUCK, Susan G, MURGO, Anthony J, MELILLO, Giovanni, SUOPING ZHAI, FIGG, William D, SWAIN, Sandra M

“…To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as…”
Get full text

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-Acid glycoprotein by FUSE, E, TANII, H, FIGG, W. D, ARBUCK, S. G, SENDEROWICZ, A. M, SAUSVILLE, E. A, AKINAGA, S, KUWABARA, T, KOBAYASHI, S, KURATA, N, KOBAYASHI, H, SHIMADA, Y, TAMURA, T, SASAKI, Y, TANIGAWARA, Y, LUSH, R. D, HEADLEE, D

Get full text